ANGO Q2 2025: Double-digit thrombectomy growth offsets margin headwind
- Enhanced Cross-Selling Synergies: The call highlighted how the combined offering of AngioVac and AlphaVac is driving cross-selling opportunities that are expanding market penetration across both devices, reflecting strong sales execution and training of the team.
- Sustained Double-Digit Growth Outlook: Executives indicated expectations for sequential and double-digit year-over-year growth in the mechanical thrombectomy segment, suggesting that the momentum from the current quarter will continue into the back half of the year.
- Positive European Market Feedback: The Q&A discussed strong feedback on the limited market release of Auryon in EU countries with plans for a full market launch later, positioning the company for expanded revenue opportunities internationally.
- Manufacturing Transition Risk: The ongoing transfer of manufacturing from Queensbury to Costa Rica could lead to double-paying overhead and temporary under-absorption, potentially pressuring gross margins in the back half of the year.
- Uncertainty in European Market Penetration: Limited market release feedback and complex reimbursement dynamics in the EU for products like Auryon may delay a full market launch and result in slower revenue contributions from this region.
- Reliance on Pending Clinical and Regulatory Outcomes: The expansion of AlphaVac, particularly outside the U.S., depends on upcoming trial data (e.g., RECOVER-AV), which, if not favorable, could hinder market adoption and revenue growth.
-
Thrombectomy Growth
Q: What drove AngioVac’s acceleration and pipeline sustainability?
A: Management emphasized that enhanced sales training and a comprehensive portfolio combining AngioVac and AlphaVac have driven strong, sustainable growth with solid clinical support and effective cross-selling. -
Mechanical Outlook
Q: What is the back-half outlook for thrombectomy?
A: They expect the mechanical thrombectomy portfolio to continue delivering double-digit sequential and year-over-year growth, as both devices work together to secure market share. -
Auryon Dynamics
Q: How is Auryon performing and evolving?
A: The team highlighted robust performance with a strategic shift toward hospital customers, while addressing complex European reimbursement issues with targeted efforts. -
Margin Impact
Q: How will gross margin be affected later this year?
A: Management noted that improved technology mix will boost margins, although temporary overhead from the ongoing manufacturing transfer might slightly temper these gains. -
EU Auryon Launch
Q: What’s the status of Auryon’s EU market launch?
A: Positive initial feedback has been received from the limited market release, with a full launch anticipated to add small single-digit revenue by year-end. -
AlphaVac RECOVER-AV
Q: Will the RECOVER-AV trial delay EU AlphaVac sales?
A: They expect U.S. sales to remain strong without delay, while continuing data generation in Europe through RECOVER-AV to support long-term market adoption.
Research analysts covering ANGIODYNAMICS.